Rhumbline Advisers Intellia Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 162,749 shares of NTLA stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
162,749
Previous 175,335 7.18%
Holding current value
$2.33 Million
Previous $3.92 Million 14.76%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$19.72 - $27.36 $248,195 - $344,352
-12,586 Reduced 7.18%
162,749 $3.34 Million
Q2 2024

Aug 01, 2024
BUY
$20.02 - $27.22 $176,115 - $239,454
8,797 Added 5.28%
175,335 $3.92 Million
Q1 2024

May 09, 2024
BUY
$23.82 - $32.8 $75,747 - $104,303
3,180 Added 1.95%
166,538 $4.58 Million
Q4 2023

Feb 08, 2024
SELL
$23.16 - $32.34 $14,521 - $20,277
-627 Reduced 0.38%
163,358 $4.98 Million
Q3 2023

Nov 09, 2023
BUY
$31.62 - $45.78 $49,896 - $72,240
1,578 Added 0.97%
163,985 $5.19 Million
Q2 2023

Aug 08, 2023
BUY
$34.58 - $46.03 $504,729 - $671,853
14,596 Added 9.87%
162,407 $6.62 Million
Q1 2023

May 11, 2023
BUY
$33.3 - $44.82 $117,648 - $158,349
3,533 Added 2.45%
147,811 $5.51 Million
Q4 2022

Feb 14, 2023
BUY
$33.21 - $62.69 $546,238 - $1.03 Million
16,448 Added 12.87%
144,278 $5.03 Million
Q3 2022

Nov 10, 2022
BUY
$53.92 - $71.7 $445,918 - $592,959
8,270 Added 6.92%
127,830 $7.15 Million
Q2 2022

Aug 11, 2022
BUY
$38.49 - $76.21 $820,337 - $1.62 Million
21,313 Added 21.69%
119,560 $6.19 Million
Q1 2022

May 12, 2022
BUY
$58.27 - $118.99 $152,667 - $311,753
2,620 Added 2.74%
98,247 $7.14 Million
Q4 2021

Feb 10, 2022
SELL
$100.76 - $138.36 $317,897 - $436,525
-3,155 Reduced 3.19%
95,627 $11.3 Million
Q3 2021

Nov 12, 2021
BUY
$132.37 - $176.78 $41,696 - $55,685
315 Added 0.32%
98,782 $13.3 Million
Q2 2021

Aug 05, 2021
BUY
$60.88 - $161.91 $88,032 - $234,121
1,446 Added 1.49%
98,467 $15.9 Million
Q1 2021

May 06, 2021
SELL
$46.59 - $83.68 $233,648 - $419,655
-5,015 Reduced 4.91%
97,021 $7.79 Million
Q4 2020

Feb 10, 2021
BUY
$18.83 - $63.53 $77,372 - $261,044
4,109 Added 4.2%
102,036 $5.55 Million
Q3 2020

Nov 12, 2020
BUY
$17.47 - $24.93 $108,104 - $154,266
6,188 Added 6.75%
97,927 $1.95 Million
Q2 2020

Aug 13, 2020
BUY
$11.14 - $22.87 $179,431 - $368,367
16,107 Added 21.3%
91,739 $1.93 Million
Q1 2020

May 06, 2020
BUY
$9.44 - $15.58 $60,019 - $99,057
6,358 Added 9.18%
75,632 $925,000
Q4 2019

Feb 05, 2020
BUY
$10.43 - $17.67 $33,678 - $57,056
3,229 Added 4.89%
69,274 $1.02 Million
Q3 2019

Oct 23, 2019
BUY
$13.07 - $18.51 $65 - $92
5 Added 0.01%
66,045 $882,000
Q2 2019

Aug 14, 2019
BUY
$13.88 - $18.41 $169,238 - $224,473
12,193 Added 22.64%
66,040 $1.08 Million
Q1 2019

May 01, 2019
BUY
$12.79 - $17.62 $73,107 - $100,715
5,716 Added 11.88%
53,847 $920,000
Q4 2018

Jan 31, 2019
BUY
$11.39 - $27.13 $205,589 - $489,696
18,050 Added 60.0%
48,131 $657,000
Q3 2018

Nov 07, 2018
SELL
$25.78 - $32.6 $52,204 - $66,015
-2,025 Reduced 6.31%
30,081 $861,000
Q2 2018

Aug 06, 2018
BUY
$20.02 - $30.79 $304,324 - $468,038
15,201 Added 89.92%
32,106 $878,000
Q1 2018

May 02, 2018
BUY
$19.43 - $34.95 $22,441 - $40,367
1,155 Added 7.33%
16,905 $357,000
Q4 2017

Feb 09, 2018
SELL
$17.39 - $31.12 $29,667 - $53,090
-1,706 Reduced 9.77%
15,750 $303,000
Q3 2017

Nov 06, 2017
BUY
$15.16 - $25.75 $264,632 - $449,492
17,456
17,456 $434,000

Others Institutions Holding NTLA

# of Institutions
313
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email